Abortive cell culture infections of nuclear polyhedrosis viruses as model systems for host specificity.

Descreve-se a proliferacao do virus e o efeito citopatico numa infeccao abortiva que envolve o virus de poliedrose nuclear de Autographa californica (AcMNPV) e uma linhagem de Bombyx mori. Os resultados indicam que o AcMNPV acarreta efeitos citopaticos (CPE) complexos e raros nas calulas do B. mori. Tal fato envolve a formacao de sacos e protrusoes, alem da hipertrofia e arredondamento do nucleo, normalmente observados em infeccoes produtivas. A infeccao de celulas de B. mori com AcMNPV inativado por raios ultravioleta induz a formacao somente de sacos, o que indica que a expressao genica virial nao e necessaria para este efeito. Nas celulas de B. mori nenhum virus infeccioso e produzido. A microscopia eletronica mostra que somente o estroma virogenico é formado nas celulas de B. mori e nao os virions ou PIBs (corpos de inclusao poliedricos). Detectam-se nucleocapsideos em 20% de celulas infectadas, porem estes sao defectivos. Os resultados sugerem que um componente virial de virus de poliedrose nuclear (NPV) causa efeito citopatico. Este principio tem importantes implicacoes na identificacao de genes virais visando a producao de plantas transgenicas resistentes a insetos-praga.Made available in DSpace on 2011-04-09T12:15:12Z (GMT). No. of bitstreams: 1 pab12abresp92.pdf: 3583080 bytes, checksum: e73097eb71c8af3fe1d2bb39b8e69aa4 (MD5) Previous issue date: 2001-08-27199

Kinetic analysis of in vitro production of wild-type Spodoptera frugiperda nucleopolyhedrovirus

In this study, the kinetic behavior of Sf9 and Sf21 cells used in the production of a baculovirus biopesticide to control the pest of corn Spodoptera frugiperda was analyzed. Kinetic variables such as maximum specific growth rate, cell productivity, mean rate of infection, as well as the mean rate of occlusion body production were determined during the infection of these cell-lines with the extracellular virus of the S. frugiperda nucleopolyhedrovirus (SfMNPV). The Sf9 cell-line resulted in better viral production results (5.0 x 10 OB/mL) than the Sf21 cell-line (2.5 x 10 OB/mL)

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Answer questions and earn CME/CNE. To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria. Key changes in the eighth edition AJCC Cancer Staging Manual include: 1) tumor thickness measurements to be recorded to the nearest 0.1 mm, not 0.01 mm; 2) definitions of T1a and T1b are revised (T1a, <0.8 mm without ulceration; T1b, 0.8-1.0 mm with or without ulceration or <0.8 mm with ulceration), with mitotic rate no longer a T category criterion; 3) pathological (but not clinical) stage IA is revised to include T1b N0 M0 (formerly pathologic stage IB); 4) the N category descriptors “microscopic” and “macroscopic” for regional node metastasis are redefined as “clinically occult” and “clinically apparent”; 5) prognostic stage III groupings are based on N category criteria and T category criteria (ie, primary tumor thickness and ulceration) and increased from 3 to 4 subgroups (stages IIIA-IIID); 6) definitions of N subcategories are revised, with the presence of microsatellites, satellites, or in-transit metastases now categorized as N1c, N2c, or N3c based on the number of tumor-involved regional lymph nodes, if any; 7) descriptors are added to each M1 subcategory designation for lactate dehydrogenase (LDH) level (LDH elevation no longer upstages to M1c); and 8) a new M1d designation is added for central nervous system metastases. This evidence-based revision of the AJCC melanoma staging system will guide patient treatment, provide better prognostic estimates, and refine stratification of patients entering clinical trials. CA Cancer J Clin 2017;67:472-492. © 2017 American Cancer Society. © 2017 American Cancer Societ